Be The Match BioTherapies and Cryoport Join Forces to Propel Cell and Gene Therapy Advancements
In a groundbreaking move, Be The Match BioTherapies®, a pioneering organization that offers solutions for companies venturing into the development and commercialization of cell and gene therapies, has announced a strategic partnership with Cryoport, a global leader in providing innovative products and services to the rapidly evolving cell & gene therapy sector. A Partnership for […]
How Multipotent Stem Cells are Changing the Landscape of Cell Therapy
We’re about to embark on a journey that will take us deep into the heart of cell therapy, a field that’s changing the face of medicine as we know it. Now, when we say “stem cell,” what comes to mind? You might be thinking of a sort of “master cell” that has the potential to […]
Cell BioEngines Enters into an Exclusive Worldwide Agreement to Develop and Commercialize Potent Immune Cell States to Cure Cancer
BOSTON and NEW YORK, Jan. 25, 2023 (GLOBE NEWSWIRE) — Cell BioEngines Inc. (the “Company”), a cell and gene therapy company focused on developing an allogenic cell-based product for solid tumors, today announced that it has entered into an exclusive license agreement with Icahn School of Medicine at Mount Sinai (“Icahn Mount Sinai”), in New […]
First US leukemia patient dosed with Smart Immune’s investigational SMART101 cell therapy
Smart Immune SAS, a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T-cell therapy platform to fully and rapidly re-arm the immune system, announced today that the first adult leukemia patient has been dosed with SMART101, a T-cell progenitor cell injection derived from donor stem cells using ProTcell at Memorial Sloan Kettering Cancer Center (MSK). The Phase […]
Cell and Gene Therapy Companies Leverage GenScript’s cGMP sgRNA Capability to Accelerate Speed to Market
PISCATAWAY, N.J., Dec. 15, 2022 /PRNewswire/ — GenScript USA Inc., the world’s leading life-science service provider, recently expanded its global current Good Manufacturing Practices (cGMP) single-guide RNA (sgRNA) manufacturing capabilities to meet the growing demand for cell and gene therapies. GenScript’s 400,000 square-foot cGMP facility enables next-generation gene and cell therapy R&D programs to advance IND filings and clinical trials. “We are […]
ExCellThera announces completion of Phase 2 clinical trials for UM171-expanded cell therapy in high-risk blood cancers
MONTREAL, Nov. 15, 2022 (GLOBE NEWSWIRE) — ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today the completion of patient enrollment in its initial Phase 2 studies for high-risk leukemias and myelodysplastic syndromes (MDS). ECT-001 Cell Therapy, ExCellThera’s most advanced investigational drug, combines the proprietary molecule UM171 and an […]
Replay establishes distinguished Scientific Advisory Board of genomic medicine and cell therapy experts
San Diego, California and London, UK, October 17, 2022 – Replay, a genome writing company reprogramming biology by writing and delivering big DNA, today announced that it has established a scientific advisory board (SAB) comprising ten experts across a broad range of areas of scientific importance in genomic medicine and cell therapy. The newly formed SAB will provide input into […]
What is Gene Therapy?
Gene therapy has been studied for more than 40 years and can help stop or slow the effects of disease on the most basic level of the human body—our genes. And to understand how it works, we’ll start at the basics. Here’s a great video from the American Society for Gene & Cell Therapy to […]
What is the Difference Between Gene Therapy, Cell Therapy, and Gene Editing?
Gene therapy, cell therapy and gene editing are fields of biomedical research with similar goals in mind: To treat disease by changing our bodies at a microscopic level. Specifically, these approaches aim to change our genetic makeup. However, each one changes our genetic material in slightly different ways. What do these approaches have in common, […]